Polymorphic form of meisoindigo and modified formulation of meisoindigo
AssigneeStatia Biopharma Inc.
InventorLonggui Wang
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel crystal form, manufacturing procedures, pharmaceutical compositions, formulations and medicaments comprising a N-methylisoindigo crystalline, methods of preparation, and the use of the N-methylisoindigo crystalline to prepare a medicament to prevent cancer, or treat cancer or an inflammatory-related disease associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines.
Claims20
A solid form of N-methylisoindigo or a solid crystal form of N-methylisoindigo (Crystal Form I) having an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 7.71°.
Dependencies are inferred from the claim text.